patients

Press Release: Sanofi and Regenerons Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous…

3 weeks ago

Menarini Group Announces New Data on ELZONRIS (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition

Data spans five abstracts including two oral presentations with important findings for patients living with blastic plasmacytoid dendritic cell neoplasm (BPDCN)BPDCN…

3 weeks ago

Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial

Company Announces Approximately $30 Million in Cash and Short-Term Investments Following Its October 27th Registered Direct Offering November 24, 2025…

3 weeks ago

MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025

Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase…

3 weeks ago

National Cancer Institute Broadens Partnership with Medidata to Bring Unmatched Continuity of Medical and Clinical Data for Lead Protocol Organizations

The Medidata Data Experience offering will enable the National Cancer Institute Lead Protocol Organizations to expedite the development of life-saving…

3 weeks ago

Aeroflow Health Named to The Healthcare Technology Report’s Top 50 Healthcare Technology Companies of 2025

ASHEVILLE, N.C., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Aeroflow Health, a healthcare company pioneering technology for medical products and services,…

4 weeks ago

Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs

Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) is issuing the following…

1 month ago

Invictus Pharmacy First to Accept Crypto for Prescriptions

Disrupting pharmacy payments with ETH, SOL, and XRP acceptance nationwide; online rollout set for Jan. 1, 2026. NEW YORK, Nov. 13,…

1 month ago

Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results

CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc., previously known as Leap Therapeutics, Inc. (Nasdaq:LPTX), a company developing novel…

1 month ago

GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF

EVerZom’s investigational drug candidate EViv, developed to treat ACLF, using its proprietary exosome platform, represents a novel approach to regenerative…

1 month ago